ArticleNature communications2022
Rapid antigen testing as a reactive response to surges in nosocomial SARS-CoV-2 outbreak risk.
Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 28 citations in OpenAlex.
- Advancing Laboratory Diagnostics for Future Pandemics: Challenges and Innovations.Pathogens (Basel, Switzerland) · 2025Review
- Article
- Implementing SARS-CoV-2 Testing during a Large-Scale Sporting Event in Africa: Lessons Learned from the Africa Football Cup of Nations Tournament in Cameroon.The American journal of tropical medicine and hygiene · 2025Article
- The role of economic evaluation in modelling public health and social measures for pandemic policy: a systematic review.Cost effectiveness and resource allocation : C/E · 2024Article
- Rapid deep learning-assisted predictive diagnostics for point-of-care testing.Nature communications · 2024Article
- Proposed new definition for hospital-acquired SARS-CoV-2 infections: results of a confirmatory factor analysis.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2024Article
- Evaluating the impact of test-trace-isolate for COVID-19 management and alternative strategies.PLoS computational biology · 2023Article
- Collateral impacts of pandemic COVID-19 drive the nosocomial spread of antibiotic resistance: A modelling study.PLoS medicine · 2023Article
- Is there a role for RDTs as we live with COVID-19? An assessment of different strategies.BMJ global health · 2023Article
- Dual-mode SERS-based lateral flow assay strips for simultaneous diagnosis of SARS-CoV-2 and influenza a virus.Nano convergence · 2022Article
- Rapid Antigen Diagnostics as Frontline Testing in the COVID-19 Pandemic.Small science · 2022Article
- Projections of the transmission of the Omicron variant for Toronto, Ontario, and Canada using surveillance data following recent changes in testing policies.Infectious Disease Modelling · 2022Article
- Rapid antigen testing as a reactive response to surges in nosocomial SARS-CoV-2 outbreak risk.Nature communications · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Healthcare facilities are vulnerable to SARS-CoV-2 introductions and subsequent nosocomial outbreaks. Antigen rapid diagnostic testing (Ag-RDT) is widely used for population screening, but its health and economic benefits as a reactive response to local surges in outbreak risk are unclear. We simulate SARS-CoV-2 transmission in a long-term care hospital with varying COVID-19 containment measures in place (social distancing, face masks, vaccination). Across scenarios, nosocomial incidence is reduced by up to 40-47% (range of means) with routine symptomatic RT-PCR testing, 59-63% with the addition of a timely round of Ag-RDT screening, and 69-75% with well-timed two-round screening. For the latter, a delay of 4-5 days between the two screening rounds is optimal for transmission prevention. Screening efficacy varies depending on test sensitivity, test type, subpopulations targeted, and community incidence. Efficiency, however, varies primarily depending on underlying outbreak risk, with health-economic benefits scaling by orders of magnitude depending on the COVID-19 containment measures in place.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.